What is KRYS's P/E ratio?

KRYSTAL BIOTECH INC (KRYS) currently trades at a P/E ratio of 48.06.

KRYSTAL BIOTECH INC reports a Return on Equity (ROE) of 17.63%.

What is KRYS's dividend yield?

KRYSTAL BIOTECH INC offers a dividend yield of 0.00%.

What is KRYS's Quality Score?

Our AI rates KRYS's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KRYS?

Our AI Timing Score for KRYS is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KRYS belong to?

KRYSTAL BIOTECH INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

KRYS (NASDAQ) Stock Analysis | KRYSTAL BIOTECH INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

KRYS AI Analysis Summary

Our AI summary for KRYS: KRYSTAL BIOTECH INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 48.06, ROE of 17.63%, a dividend yield of 0.00%. Its financial Quality Score stands at 85/100 — fundamentals stronger than most of the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

KRYS

KRYSTAL BIOTECH INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 92

USD 341.12

-25.73 (-7.01%) Day Change

Watchlist Portfolio Compare Chart

48.06

P/E

0.00

D/E

17.6%

ROE

16.1%

ROA

0.00%

Div Yield

0.21

PEG

KRYSTAL BIOTECH INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 341.12 Price -25.73 (-7.01%) Day Change	NEWS SCORE: 92

KRYS, the overall quality is very good ( Quality = 85) and the timing to buy is ...(Sign In to See)...

Loading chart...

85 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: P/E ratio is relatively high
Historical ROE is relatively low
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

57%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	92
Magic Formula Rank by ROA	1382
Magic Formula Rank by ROE	1382
Magic Formula Rank by ROIC	1347
Price	341.12
PBV / Sector	8.47 / 5.20
Earning Per Share	7.10

PE / Sector	48.06 / 19.97
PEG or PE/Growth / Sector	0.21 / 1.22 GREAT
Average 1M Daily Value	202.40 M GREAT
Average 1W Daily Value	147.77 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

68%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	53.92 / 98.71 GREAT
NPM Average (%) / Sector	39.70 / -1,721.76 GREAT
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	16.11 / 27.02 GOOD
ROA Average (%) / Sector	3.24 / -368.17
ROA Change Average (%) / Sector	128.39 / 5,404.12 GREAT
ROE (%) / Sector	17.63 / 3.47
ROE Average (%) / Sector	3.69 / 6.51
ROE Change Average (%) / Sector	137.25 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:05
Symbol	KRYS
Name	KRYSTAL BIOTECH INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	29.48 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	10,814.65 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203

Phone: 412 586 5830

Website: https://www.krystalbio.com

Employees: 295

Sector: Healthcare >> Biotechnology

Description: Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.